Big4Bio Podcast
With the JP Morgan Healthcare Conference approaching, biotech CEOs are wondering whether the new year will bring a more welcoming IPO market. Big4Bio spoke with Gregg Beloff, co-founder and managing director of Danforth Advisors, about how biotech leaders can position their companies for different financing options, the importance of achieving and communicating de-risking milestones, and why it’s never too early to capitalize on opportunities when they arise.
“Rather than focus on an IPO, companies should prepare themselves to capitalize on a range of financing options that may present themselves.“